


RECEIVED

MAR 04 2003

Please type a plus sign (+) inside this box → ☒

PTO/SB 0864, 1999

Approved for use through 10/31/99 OMB 0654-0003

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to furnish information to a collection of information unless it contains a valid OMB control number.

TECH CENTER 1600/2900

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/806,400
				Filing Date	September 30, 1999
				First Named Inventor	Shoenfeld et al
				Group Art Unit	1644
				Examiner Name	R. B. Schwadron
Sheet	1	of	4	Attorney Docket Number	01/21885

U.S. PATENT DOCUMENTS						
Examiners Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
MB	AA	4,874,795		Yesair	10-17-1989	class subclass
MB	AB	5,409,710		Leonard	04-25-1995	- -
MB	AC	6,225,070		Witzum et al	05-01-2001	- -

FOREIGN PATENT DOCUMENTS								
Examiners Initials	Cite No. ¹	Foreign Patent Documents			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Class subclass Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
MB	AD	WO	98/16248	A1	The Government of the United States of America, represented by The Secretary, Department of Health and Human Services	04-23-1998	- -	

Examiner Signature		Date Considered	5/14/2001
-----------------------	--	--------------------	-----------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

MAR 04 2003

Please type a plus sign (+) inside this box → ☒

PTO/SB/08-1096

Approved for use through 10/31/99 OMB 063-10631

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to furnish information to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/806,400
Filing Date	September 30, 1999
First Named Inventor	Shoenfeld et al
Group Art Unit	1644
Examiner Name	R. B. Schwadron
Attorney Docket Number	01/21885

Sheet 2 of 4

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RB	AE	Blanas, et al., Induction of Autoimmune Diabetes by Oral Administration of Autoantigen, Science, 274(5293): 1707-1712	
	AE	Peck, et al., LDL modifications et atherosclerose, Nature des modifications: Proprietes physicochimiques et biologiques, Ann Biol Clin (1992), 50, 213-227	
MS	AG	Mol, et al., The role of modification of lipoproteins and of the immune system in early atherogenesis, Netherlands Journal of Medicine, 43 (1993) 83-90	
	AH	Hoff, et al., Structure of cholesterol-containing particles accumulating in atherosclerotic lesions and the mechanisms of their derivation, Current Opinion in Lipidology 1995, 6:317-325	
	AI	Shen, et al., From interaction of lipidic vehicles with intestinal epithelial cell membranes to the formation and secretion of chylomicrons, Advanced Drug Delivery Reviews, 50 (2001) S103-S125	
	AJ	Maurer, et al., Developments in liposomal drug delivery systems, Expert Opin. Biol. Ther. (2001) 1(6) pp 1-25	
	AK	Emeson et al., Accelerated Atherosclerosis in Hyperlipidemic C57BL/6 Mice Treated with Cyclosporin A, American Journal of Pathology, Vol. 142, No. 6, June 1993, pp. 1906-1915	
	AL	Meir et al., Inflammation in atherosclerosis – causal or casual? Dept. Pathology (K.M.), the Center for Research, Prevention and Treatment of Atherosclerosis, pp. 1-5	
	AM	Williams, et al., Rodent models of arthritis: relevance for human disease, Clin. Exp. Immunol. 1998: 114:330-332	

Examiner Signature		Date Considered	5/14/2003
--------------------	--	-----------------	-----------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

MAR 04 2003

Please type a plus sign (+) inside this box → ☒

PTO/STP-A (10-96)

Approved for use through 10/31/99 OIA 1003-1003

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to furnish information to a collection of information unless it contains a valid OMB control number.

TECH CENTER 1600/2900

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	09/806,400
				Filing Date	September 30, 1999
				First Named Inventor	Shoenfeld et al
				Group Art Unit	1644
				Examiner Name	R. B. Schwadron
Sheet	3	of	4	Attorney Docket Number	01/21885

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
VBS	AN	Fujinami, et al., Myelin Basic Protein Serum Factor: An Endogenous Neuroantigen Influencing Development of Experimental Allergic Encephalomyelitis in Lewis Rats, Brief Definitive Report , J. Exp. Med., Vol. 148, December 1978, pp. 1716-1721	
	AO	Ogra et al., Vaccination Strategies for Mucosal Immune Response, Clinical Microbiology Reviews, Vol. 14, No. 2, Apr. 2001, pp. 430-445	
	AP	Lehner et al., The Effect of Route of Immunization on Mucosal Immunity and Protection, The Journal of Infectious Diseases, 1999:179(Suppl 3):S489-S492	
	AQ	Chen, Recent advances in mucosal vaccine development, Journal of Controlled Release 67 (2000) pp. 117-128	
	AR	Palinski, et al., Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis, Proc. Natl. Acad. Sci, USA, Vol. 92, January 1995, pp. 821-825	
	AS	George et al., Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis, Atherosclerosis 138 (1998) pp. 147-152	
	AT	Freigang, et al., Immunization of LDL Receptor-Deficient Mice with Homologous Malondialdehyde-Modified and Native LDL Reduces Progression of Atherosclerosis by Mechanisms Other Than Induction of High Titers of Antibodies to Oxidative Neopeptides, Arterioscler Throm Vasc Biol, December 1998, pp. 1972 –1982	

Examiner Signature		Date Considered	5/14/2002
--------------------	--	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Unique citation designation number. ². Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

MAR 04 2003

TECH CENTER 1600/2900

PTO/SB/08A (10-96)


Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	09/806,400		
		Filing Date	September 30, 1999		
		First Named Inventor	Shoenfeld et al		
		Group Art Unit	1644		
		Examiner Name	R. B. Schwadron		
Sheet	4	of	4	Attorney Docket Number	01/21885

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
P31	AU	Zhou, et al., LDL Immunization Induces T-Cell-Dependent Antibody Formation and Protection Against Atherosclerosis, Arterioscler Throm Vasc Biol, January 2001, pp. 108–114	
	AV	Modified lipoproteins, 11 th International Symposium on Atherosclerosis, Paris, October 1997, pp. 227, 289	
	AW	Mol. et al., The role of modification of lipoproteins and of the immune system in early atherogenesis, Neth J Med 1993 August;43(1-2):83-90	
	AX	Pech et al., Modified LDL and atherosclerosis. Nature of modifications. Physicochemical and biological properties, Ann Biol Clin (Paris) 1992;50(4):213-227	

Examiner Signature		Date Considered	5/14/2003
--------------------	---	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Unique citation designation number. ². Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.